FINWIRES · TerminalLIVE
FINWIRES

Eni Hosts Iraq Methane Initiative as Emissions Drop 40% at Zubair Field

-- Eni (E) said Tuesday it hosted Iraqi stakeholders in Basra to advance methane monitoring, as emissions cuts at the Zubair field reached about 40%.

The company brought together officials from Iraq's oil and environment ministries, national oil companies, and representatives of the Clean Air Task Force for a technical knowledge-sharing initiative.

The effort supports Iraq's emissions strategy following its 2021 Global Methane Pledge commitment to cut methane output by 30% by 2030, the company said.

Eni said it is also working with local partners under the Oil and Gas Methane Partnership 2.0, a United Nations-backed program focused on tracking and reducing emissions.

The program included a field session at the Zubair Initial Production Facility using optical gas imaging tools to detect, record, and manage methane emissions data.

The practical demonstration highlighted the benefits of transferring technical skills to Iraqi professionals supporting national oil companies in emissions monitoring, the company added.

Eni, lead contractor at the Zubair field for Basrah Oil, is working with local partners to reduce greenhouse gas emissions, focusing on methane and gas flaring, Eni said.

The company is targeting zero routine flaring at Zubair by 2027 while continuing its leak detection and repair campaign introduced between 2022 and 2024.

Implementation of the LDAR campaign reduced fugitive emissions by about 40% in 2025 compared with the previous year, according to the company.

Zubair became the first Iraqi field to consistently apply the LDAR program, attracting support from international groups helping develop national emissions guidelines, Eni said.

Price: $55.20, Change: $-0.81, Percent Change: -1.46%

相關文章

Asia

Dizal Pharma將在美國臨床腫瘤學會年會上發表三種藥物的研究成果。

根據週三在上海證券交易所發布的公告顯示,江蘇迪扎爾製藥(SHA:688192)表示,將在美國臨床腫瘤學會(ASCO)年會上公佈其新藥sunvozertinib片劑、golidocitinib膠囊和DZD6008的最新研究成果。 sunvozertinib和DZD6008皆用於治療非小細胞肺癌,而golidocitinib則用於治療T細胞淋巴瘤。研究結果顯示,這些藥物均取得了正面成果,尤其是DZD6008,其具有顯著的抗腫瘤活性且安全性良好。 該生技公司的股價在午盤交易中上漲不到2%。

$SHA:688192
Asia

Critica將於3月季度啟動西澳大利亞稀土計畫範圍界定研究。

根據週三提交給澳洲證券交易所的文件顯示,Critica(ASX:CRI)表示,位於西澳大利亞的Jupiter稀土計畫的初步研究已於今年3月季度正式啟動。 該研究整合了選礦、下游加工、基礎設施和開發假設,旨在確定一個基準開發路徑。 公司計劃在6月季度繼續完成Jupiter專案140個鑽孔的資源升級鑽探工作。此外,該公司還計劃準備並運送20,000公斤散裝樣品進行中試規模處理,以支援持續的最佳化、性能提升和中間精礦的生產。

$ASX:CRI
Asia

北太平洋銀行的收購要約確保了對卡里爾銀行的控制權

北太平洋銀行(東京證券交易所代號:8524)週三在東京證券交易所發佈公告稱,其對Career Bank的股份收購要約已獲成功,持股比例增至88.26%,使Career Bank成為其子公司。 北太平洋銀行此次收購了852,487股Career Bank股份,超過了完成交易所需的最低收購數量。 交易結算將於4月28日開始,屆時Career Bank將正式併入北太平洋銀行的財務報表。 北太平洋銀行計劃啟動相關程序,使Career Bank成為其全資子公司,並將其股票從札幌證券交易所下市。此次收購總成本約為15億日圓。

$TYO:8524